Latest
Company News
Friday 3 February, 2006. Latest clinical data on BiOracle's
diagnostic test for candida demonstrates that it is more effective than culture
and microscopy in the diagnosis of vaginal candidiasis (thrush) .
More
details...
Tuesday 6 September, 2005. Hygis SA launches BiOracle's
diagnostic test for candida in Switzerland as "Hygis Test
Candidose". More
details...
Monday 11 April, 2005. BiOracle appoints Hygis SA as
distributor of its rapid point-of-care diagnostic test for
candida infection in Switzerland. More
details...
15 October 2004. BiOracle announces restructuring of
its senior management team. More
details...
6 April 2004. BiOracle's novel point-of-care
diagnostic test for Acute Appendicitis featured in the Daily
Mail. More
details...
29 March 2004. DMI Biosciences Inc announces license agreement
with BiOracle Ltd for novel point-of-care
diagnostic test for Acute Appendicitis. More
details...
15 March 2004. BiOracle Ltd and SensAm Ltd enter into
a collaborative agreement to develop and market an important new
point-of-care test for the detection of H. pylori. More
details...
11 March 2004. BiOracle Ltd enters into an agreement
with DMI Biosciences Inc to acquire DMI's point-of-care
diagnostic test for thrush. More
details...
1 May 2003. BiOracle launches as a new healthcare
company focusing on preventive care. More
details....
Friday 3 February, 2006. Latest
clinical data on BiOracle's
diagnostic test for candida demonstrates that it is more
effective than culture and microscopy in the diagnosis of
vaginal candidiasis (thrush).
Clinical evaluation of YeasTest, BiOracle's point-of-care
diagnostic test for vaginal candidiasis (thrush) has shown that
the test is more sensitive and also more specific for candida
infection than either culture or microscopy, the two most
commonly used diagnostic techniques for vaginitis.
In the study, YeasTest had sensitivity of 85.1% (compared to
74.6% for culture and 58.7% for microscopy) and specificity of
92.6% (compared to 88.0% for culture and 85.5% for microscopy).
YeasTest's overall efficiency rating was 91.5% (compared to
85.9% for culture and 78.2% for microscopy).
High diagnostic accuracy, allied to YeasTest's convenience
and ease of use at the point of care, make it an ideal
diagnostic test for use by a range of healthcare practitioners
as an aid to the diagnosis of vulvovaginal candidiasis.
Further details are available from BiOracle on request.
Source: BiOracle Limited
Tuesday 6 September, 2005. Hygis SA launches BiOracle's
diagnostic test for candida in Switzerland as "Hygis Test
Candidose".
Tuesday 6 September, 2005. Hygis SA has now launched BiOracle’s
new rapid diagnostic test for vaginal candidiasis in Switzerland
and Liechtenstein as “Hygis Test Candidose”.
With its rapid, point-of-care test format, Hygis Test
Candidose combines excellent diagnostic accuracy with much
greater convenience compared to other standard diagnostic
techniques. Consequently, Hygis Test Candidose offers
significant benefits to both healthcare practitioners and to
patients.
BiOracle Limited is a privately-held healthcare company based
in the North West of England, that commercialises innovative
healthcare products with a focus on preventive care.
Hygis SA is a private Swiss healthcare company distributing
innovative niche healthcare products throughout Switzerland.
Hygis’s primary focus is on Gynaecology and myorelaxants.
Source: BiOracle Limited
Monday 11 April, 2005. BiOracle
Appoints Hygis SA as distributor of its rapid point-of-care diagnostic
test for candida infection in Switzerland
BiOracle Limited (BiOracle, www.bioracle.co.uk) announced
today the appointment of Hygis SA as a distributor of its rapid
point-of-care diagnostic test for candida infection. The
agreement covers the territories of Switzerland and
Liechtenstein.
Vaginal candidiasis (also known as thrush) affects
three-quarters of all women at least once in their lives. In one
in five cases, women experience a more persistent form of the
condition, known as recurrent thrush. Diagnosis of candida
infection is typically confirmed by microscopic examination or
by culturing from a vaginal sample. Neither method can deliver
the speed and accuracy of diagnosis required in today's
demanding healthcare environment. Candidiasis can often be
confused with other forms of vaginitis, including bacterial
vaginitis, resulting in inappropriate treatment and unnecessary
discomfort for the patient.
BiOracle's new diagnostic test delivers high diagnostic
accuracy in a test format that can simply and rapidly be used at
the point of care, offering significant benefits for doctors and
patients alike.
"There is an excellent fit between Hygis's existing
female health business and our rapid diagnostic test for vaginal
candidiasis," said Michael Spencer, CEO of BiOracle.
"We are delighted to be working with Hygis to bring this
exciting new product to a wider audience, helping to broaden the
'test and treat' paradigm into another medical condition".
"Hygis is already very active in the prevention and cure
of vaginal infections. Adding BiOracle's excellent rapid
diagnostic test will be of great help to our customers in their
battle against candidiasis" said Denis Amman, CEO of Hygis.
BiOracle Limited is a privately-held healthcare company based
in the North West of England, that commercialises innovative
healthcare products with a focus on preventive care.
Hygis SA is a private Swiss healthcare company distributing
innovative niche healthcare products throughout Switzerland.
Hygis's primary focus is on Gynaecology and myorelaxants.
Source: BiOracle Limited
15 October 2004.
BiOracle announces restructuring of its senior management team.
The Board of Directors of BiOracle Ltd announce that CEO, Bruce
Murdoch, is standing down with immediate effect to pursue
other interests. He will remain on the Board as a non-executive
director.
Michael Spencer, currently a non-executive director of
BiOracle is appointed CEO of the company. Michael was previously
a partner in Accenture plc's Health and Life Sciences practice
and held a number of senior positions during his 15 year tenure
there. His roles mainly focused on the Regulatory and Clinical
Development areas, and the Commercial to R&D interface.
BiOracle intends to utilise Michael's programme management
experience and network of contacts within the industry.
John Clinton assumes additional responsibilities as
Commercial Director.
Artie Chalmers remains as Finance Director.
Commenting on the recent changes, Michael Spencer said that
we are now in a position to take our company forward to
implementation through a series of licensing deals.
BiOracle is a Cheshire, UK based company, which licenses and
markets a range of "point of care" diagnostic
products. For further information see www.bioracle.co.uk
Click here for further background on biOracle.
6 April 2004. BiOracle's
novel point-of-care
diagnostic test for Acute Appendicitis featured in the Daily
Mail.
The
following article was featured in the UK's Daily Mail
newspaper.
How to beat appendix op
by PAT HAGAN, Daily Mail
 new test for
appendicitis could save hundreds of patients from unnecessary
operations. The simple test looks for a marker in urine that
indicates whether severe stomach pain is really being caused by
an inflamed appendix.
If the marker is present, surgeons can operate quickly to
remove the organ. If it's not present, they know something else
is causing the pain.
Current diagnostic techniques are far from perfect because
many diseases can cause the same symptoms as appendicitis. In as
many as 30 per cent of cases, surgeons open up a patient only to
find their appendix is perfectly healthy.
The appendix is a small worm-like pouch attached to the large
bowel. Its exact function remains unknown but it can become
inflamed, causing waves of pain in the abdomen. After a few
hours the pain worsens, temperature soars and the patient feels
sick.
Agony of appendicitis
Most patients with appendicitis turn up at casualty
departments in agony. Doctors usually take a medical history and
a blood or urine sample to check for raised white blood cell
count - a sign of infection.
They also examine the abdomen by pressing on it to see where
the pain is coming from. The most common cure is an operation
that involves making a two-inch incision in the lower part of
the abdomen and removing the appendix under a general
anaesthetic. Most patients need to stay in hospital for up to
three days afterwards.
Actress Kate Beckinsale recently suffered appendicitis and
was rushed to hospital in LA. She underwent an emergency
operation and has now recovered completely.
The new test works by looking for a specific chemical which
is released by the organism that triggers appendicitis. This can
be detected in the urine of an affected person within hours of
the first symptoms.
Test takes 15 minutes
The urine test takes just 15 minutes and is expected to be
available in the UK early next year. It is hoped A&E
departments will stock it in order to help doctors accurately
diagnose the condition.
Called Appytest, it is designed to be used as a back-up to
blood checks. BiOracle Limited, a Cheshire-based firm that will
be marketing the product in the UK, says it is easy to use,
cheap and accurate.
"It takes about 15 minutes and will be very
affordable," says company spokesman Bruce Murdoch.
"None of these kind of tests are completely foolproof, but
ours is 80 to 90 per cent accurate.
"If a test result comes back negative and the white
blood-cell count is also negative, then we would advise keeping
the patient under observation for 24 hours. Because the test
will be cheap, it can be repeated after a few hours."
Source: http://www.femail.co.uk/pages/standard/article.html?in_article_id=211050&in_page_id=169
29 March 2004. DMI
Biosciences Inc announces license agreement with biOracle Ltd for
novel point-of-care diagnostic test for Acute Appendicitis.
Monday
March 29, 2004, Englewood, Colorado – DMI BioSciences, Inc. (DMI,
www.dmibiosciences.com) announced today the licensing of its
novel point-of-care diagnostic test (APPYTEST®) for
acute appendicitis to BiOracle, Ltd. (www.bioracle.co.uk).
BiOracle was
granted exclusive, worldwide rights to develop and commercialize
DMI’s patented technology; DMI will receive milestone payments
and royalties.
Appendicitis
is the most common surgical emergency requiring an operation,
yet early diagnostic assessment relies mainly on physical
examination and signs and symptoms that can be misleading. The
new test for appendicitis will provide clinicians with a rapid,
non-invasive assay that is easy to administer, has high
diagnostic specificity and can potentially reduce unnecessary
hospitalizations and surgeries.
At present, no rapid diagnostic biomarker has high
diagnostic specificity for acute appendicitis.
|
